Document is current
Any future updates will be listed below
-
Authors
Sá, Ana Caroline C.
Webb, Amy
Gong, Yan
McDonough, Caitrin W.
Shahin, Mohamed H.
Datta, Somnath
Langaee, Taimour Y.
Turner, Stephen T.
Beitelshees, Amber L.
Chapman, Arlene B.
Boerwinkle, Eric
Gums, John G.
Scherer, Steven E.
Cooper-DeHoff, Rhonda M.
Sadee, Wolfgang
Johnson, Julie A.
-
Funding
Funding for this research was provided by:
National Institute of Health Pharmacogenetics Research Network (U01-GM074492)
National Center for Advancing Translational Sciences (UL1 TR000064, UL1 TR000454, UL1 TR000135)
Mayo Foundation for Medical Education and Research
National Institutes of Health Pharmacogenetics Research Network (U19-GM061388, U19-GM061390)
- License Information
-
More Information
Article History
Received: 19 November 2017
Accepted: 25 May 2018
First Online: 20 June 2018
Ethics approval and consent to participate
: All study participants from PEAR and PEAR-2 (NCT00246519, NCT01203852 ExternalRef removed) provided written informed consent. The Institutional Review Boards at participating clinical trial sites including the University of Florida, Mayo Clinic, and Emory University approved both PEAR and PEAR-2. The studies were conducted in accordance with the principles of the Declaration of Helsinki and the US Code of the Federal Regulations for Protection of Human Subjects.
: The authors declare that they have no competing interests.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
